Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue
Product sales	$ 730,325	$ 929,241	$ 2,705,690	$ 1,432,592
Laboratory services	23,036	23,765	182,130	87,201
Collaboration revenue	6,302	27,780	131,302	308,340
Total revenue	759,663	980,786	3,019,122	1,828,133
Operating expenses
Cost of products sold	400,001	624,635	1,269,990	788,256
Cost of services	51,802	48,467	528,733	198,691
Research and development	2,178,818	1,788,748	6,278,829	3,897,049
General and administrative	1,639,996	1,614,532	4,955,096	3,694,143
Sales and marketing	1,294,640	1,032,759	4,282,628	2,962,555
Transaction expenses	0	525,596	0	525,596
Total operating expenses	5,565,257	5,634,737	17,315,276	12,066,290
Operating loss	(4,805,594)	(4,653,951)	(14,296,154)	(10,238,157)
Other expense
Interest and other income/(expense)	623	2,513	(3,078)	9,675
Interest expense	(41,423)	(17,482)	(109,806)	(1,746,853)
Foreign currency transaction (losses)/gains	(1,269)	0	2,293	0
Change in fair value of derivative financial instruments	0	0	0	(647,342)
Total other expense	(42,069)	(14,969)	(110,591)	(2,384,520)
Loss before income taxes	(4,847,663)	(4,668,920)	(14,406,745)	(12,622,677)
Provision for income taxes	0	1,662	0	1,662
Net loss	(4,847,663)	(4,670,582)	(14,406,745)	(12,624,339)
Preferred stock dividends and beneficial conversion	0	0	(332,550)	(244,508)
Net loss available to common stockholders	$ (4,847,663)	$ (4,670,582)	$ (14,739,295)	$ (12,868,847)
Net loss per common share - basic and diluted	$ (0.23)	$ (0.38)	$ (0.92)	$ (2.00)
Weighted average shares outstanding - basic and diluted	20,938,700	12,261,238	16,028,047	6,444,373
Net loss	$ (4,847,663)	$ (4,670,582)	$ (14,406,745)	$ (12,624,339)
Other comprehensive income/(loss) - foreign currency translation	672	(49)	1,059	(49)
Comprehensive loss	$ (4,846,991)	$ (4,670,631)	$ (14,405,686)	$ (12,624,388)